Response of HER2+ breast cancer patients to allogeneic cell immunotherapy.
Michael Har-Noy
Employment or Leadership Position - Immunovative Therapies (U)
Stock Ownership - Immunovative Therapies
Wirote Lausoontornsiri
No relevant relationships to disclose
Reuven Or
No relevant relationships to disclose
Emmanual Katsanis
Research Funding - Immunovative Therapies